Jul 31, 2017

Snap stock stable as early backers get green light to sell

Dan Primack

Rebecca Zisser / Axios

Snap stock finished down nearly 1% on Monday, settling at $13.68 per share. Despite the loss, Snap executives may be breathing a giant sigh of relief that it wasn't much greater.

  • Why it matters: This was the first day that many early Snap investors – including venture capital firms – had their shares "unlocked," which means they were able to sell on the open market. As such, there was some fear that supply would swamp demand, sending Snap's share price spiraling. But that didn't happen. Overall trading volume totaled nearly 48.8 million. That's Snap's highest mark in over two months, but only the 10th-highest since the company went public in early March.
  • Context: Around 400 million shares were unlocked today, while the company's IPO price was $17 per share.
  • Thought bubble: It wouldn't be surprising if a number of unlocked investors sold a minority of their holdings today as downside protection, with the optimistic hopes that Snap's share price can recover.
  • Coming attractions: In a little more than two weeks from now, and just days after Snap reports Q2 results, company employees will be eligible to sell upwards of 782 million of their shares.

Go deeper

Caitlin Owens

Coronavirus stress tests drug industry's dependence on China

A Hong Kong commuter wears a face mask. Photo: Miguel Candela/SOPA Images/LightRocket via Getty Images

It's unclear whether the rapid spread of the novel coronavirus will actually result in prescription drug shortages, but it has undoubtedly highlighted the potential vulnerabilities of having the supply chain for American drugs so dependent on China.

Driving the news: About 150 prescription drugs — including antibiotics, generics and some branded drugs without alternatives — are at risk of shortage if the coronavirus outbreak in China worsens, per two sources familiar with a list of at-risk drugs compiled by the Food and Drug Administration.

Go deeperArrow18 mins ago - Health
Jim VandeHei

Bernie's path to the presidency

Sen. Bernie Sanders speaks yesterday during a rally at Houston University. Photo: Mark Felix/AFP via Getty Images

Lots of Democrats are in full panic that Bernie Sanders will win the nomination and get clobbered in the general election — and bring the party down, too. But the evidence, particularly the polling, doesn't back those doomsday warnings.

Why it matters: Virtually every national and swing state poll shows Sanders tied with or beating President Trump.  And, unlike every rival, he has a huge base of fervent, unshakable supporters he can only grow.

Go deeperArrow45 mins ago - Politics & Policy
Amy Harder

These swing voters don't like Trump’s environmental rollbacks

Illustration: Sarah Grillo/Axios

Swing voters in four battleground states decisively oppose President Trump’s sweeping rollbacks of environmental regulations — but it’s unlikely to sway their votes.

Why it matters: It’s voters living in states like these, including Florida and Pennsylvania, who fill pivotal roles electing America’s presidents, so we should listen.

Go deeperArrow1 hour ago - Energy & Environment